499 related articles for article (PubMed ID: 29282126)
1. The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa.
Last AR; Burr SE; Harding-Esch E; Cassama E; Nabicassa M; Roberts CH; Mabey DCW; Holland MJ; Bailey RL
Parasit Vectors; 2017 Dec; 10(1):624. PubMed ID: 29282126
[TBL] [Abstract][Full Text] [Related]
2. Spatial clustering of high load ocular Chlamydia trachomatis infection in trachoma: a cross-sectional population-based study.
Last A; Burr S; Alexander N; Harding-Esch E; Roberts CH; Nabicassa M; Cassama ETDS; Mabey D; Holland M; Bailey R
Pathog Dis; 2017 Jul; 75(5):. PubMed ID: 28472466
[TBL] [Abstract][Full Text] [Related]
3. Impact of a single round of mass drug administration with azithromycin on active trachoma and ocular Chlamydia trachomatis prevalence and circulating strains in The Gambia and Senegal.
Harding-Esch EM; Holland MJ; Schémann JF; Sillah A; Sarr B; Christerson L; Pickering H; Molina-Gonzalez S; Sarr I; Andreasen AA; Jeffries D; Grundy C; Mabey DCW; Herrmann B; Bailey RL
Parasit Vectors; 2019 Oct; 12(1):497. PubMed ID: 31640755
[TBL] [Abstract][Full Text] [Related]
4. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia.
Harding-Esch EM; Sillah A; Edwards T; Burr SE; Hart JD; Joof H; Laye M; Makalo P; Manjang A; Molina S; Sarr-Sissoho I; Quinn TC; Lietman T; Holland MJ; Mabey D; West SK; Bailey R;
PLoS Negl Trop Dis; 2013; 7(6):e2115. PubMed ID: 23785525
[TBL] [Abstract][Full Text] [Related]
5. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?
West SK; Moncada J; Munoz B; Mkocha H; Storey P; Hardick J; Gaydos CA; Quinn TC; Schachter J
J Infect Dis; 2014 Jul; 210(1):65-71. PubMed ID: 24446528
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for active trachoma and ocular Chlamydia trachomatis infection in treatment-naïve trachoma-hyperendemic communities of the Bijagós Archipelago, Guinea Bissau.
Last AR; Burr SE; Weiss HA; Harding-Esch EM; Cassama E; Nabicassa M; Mabey DC; Holland MJ; Bailey RL
PLoS Negl Trop Dis; 2014 Jun; 8(6):e2900. PubMed ID: 24967629
[TBL] [Abstract][Full Text] [Related]
7. Ocular Chlamydia trachomatis infection: elimination with mass drug administration.
Wolle MA; West SK
Expert Rev Anti Infect Ther; 2019 Mar; 17(3):189-200. PubMed ID: 30698042
[TBL] [Abstract][Full Text] [Related]
8. Ocular immune responses, Chlamydia trachomatis infection and clinical signs of trachoma before and after azithromycin mass drug administration in a treatment naïve trachoma-endemic Tanzanian community.
Ramadhani AM; Derrick T; Macleod D; Massae P; Malisa A; Mbuya K; Mtuy T; Makupa W; Roberts CH; Bailey RL; Mabey DCW; Holland MJ; Burton MJ
PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007559. PubMed ID: 31306419
[TBL] [Abstract][Full Text] [Related]
9. Mass drug administration of azithromycin for trachoma reduces the prevalence of genital Chlamydia trachomatis infection in the Solomon Islands.
Marks M; Bottomley C; Tome H; Pitakaka R; Butcher R; Sokana O; Kako H; Solomon AW; Mabey DC
Sex Transm Infect; 2016 Jun; 92(4):261-5. PubMed ID: 26888658
[TBL] [Abstract][Full Text] [Related]
10. Impact of mass drug administration of azithromycin for trachoma elimination on prevalence and azithromycin resistance of genital
Harrison MA; Harding-Esch EM; Marks M; Pond MJ; Butcher R; Solomon AW; Zhou L; Tan N; Nori AV; Kako H; Sokana O; Mabey DCW; Sadiq ST
Sex Transm Infect; 2019 Nov; 95(7):522-528. PubMed ID: 30981999
[TBL] [Abstract][Full Text] [Related]
11. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
Yohannan J; Munoz B; Mkocha H; Gaydos CA; Bailey R; Lietman TA; Quinn T; West SK
JAMA Ophthalmol; 2013 Apr; 131(4):431-6. PubMed ID: 23392481
[TBL] [Abstract][Full Text] [Related]
12. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.
West SK; Munoz B; Mkocha H; Gaydos C; Quinn T
Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1492-7. PubMed ID: 17389476
[TBL] [Abstract][Full Text] [Related]
13. The conjunctival microbiome before and after azithromycin mass drug administration for trachoma control in a cohort of Tanzanian children.
Pickering H; Ramadhani AM; Massae P; Mafuru E; Malisa A; Mbuya K; Makupa W; Mtuy T; Derrick T; Houghton J; Bailey RL; Mabey DCW; Burton MJ; Holland MJ
Front Public Health; 2022; 10():1015714. PubMed ID: 36324475
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a Single Dose of Azithromycin for Trachoma in Low-Prevalence Communities.
Wilson N; Goodhew B; Mkocha H; Joseph K; Bandea C; Black C; Igietseme J; Munoz B; West SK; Lammie P; Kasubi M; Martin DL
Ophthalmic Epidemiol; 2019 Feb; 26(1):1-6. PubMed ID: 30543311
[TBL] [Abstract][Full Text] [Related]
15. Serology for trachoma surveillance after cessation of mass drug administration.
Martin DL; Bid R; Sandi F; Goodhew EB; Massae PA; Lasway A; Philippin H; Makupa W; Molina S; Holland MJ; Mabey DC; Drakeley C; Lammie PJ; Solomon AW
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003555. PubMed ID: 25714363
[TBL] [Abstract][Full Text] [Related]
16. Population-based analysis of ocular Chlamydia trachomatis in trachoma-endemic West African communities identifies genomic markers of disease severity.
Last AR; Pickering H; Roberts CH; Coll F; Phelan J; Burr SE; Cassama E; Nabicassa M; Seth-Smith HMB; Hadfield J; Cutcliffe LT; Clarke IN; Mabey DCW; Bailey RL; Clark TG; Thomson NR; Holland MJ
Genome Med; 2018 Feb; 10(1):15. PubMed ID: 29482619
[TBL] [Abstract][Full Text] [Related]
17. Stopping azithromycin mass drug administration for trachoma: A systematic review.
Mahmud H; Landskroner E; Amza A; Aragie S; Godwin WW; de Hostos Barth A; O'Brien KS; Lietman TM; Oldenburg CE
PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009491. PubMed ID: 34237074
[TBL] [Abstract][Full Text] [Related]
18. Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions.
Biebesheimer JB; House J; Hong KC; Lakew T; Alemayehu W; Zhou Z; Moncada J; Rogér A; Keenan J; Gaynor BD; Schachter J; Lietman TM
Ophthalmology; 2009 Nov; 116(11):2047-50. PubMed ID: 19744717
[TBL] [Abstract][Full Text] [Related]
19. Mass treatment with single-dose azithromycin for trachoma.
Solomon AW; Holland MJ; Alexander ND; Massae PA; Aguirre A; Natividad-Sancho A; Molina S; Safari S; Shao JF; Courtright P; Peeling RW; West SK; Bailey RL; Foster A; Mabey DC
N Engl J Med; 2004 Nov; 351(19):1962-71. PubMed ID: 15525721
[TBL] [Abstract][Full Text] [Related]
20. Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation (ASANTE) Trial: Design and Baseline Characteristics.
Ervin AM; Mkocha H; Munoz B; Dreger K; Dize L; Gaydos C; Quinn TC; West SK
Ophthalmic Epidemiol; 2016 Dec; 23(6):347-353. PubMed ID: 27820670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
